About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Orforglipron
LY3502970
- Company
- Eli Lilly
- Mechanism
- mono GLP-1
- Route
- Oral
- Recruiting trials
- 8 recruiting
8 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026
Find a Clinical Trial Near Me
See recruiting studies for Orforglipron and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT06672549
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Not yet reported Eli Lilly and Company 125 participants Est. completion 2027-03 117 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Recruiting NCT NCT06672939
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Not yet reported Eli Lilly and Company 150 participants Est. completion 2031-01 34 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Recruiting NCT NCT07107334
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
Not yet reported University of Florida 20 participants Est. completion 2029-11 1 site Stand-aloneOther conditions: Endometrioid Endometrial AdenocarcinomaView official trial listing → -
Recruiting NCT NCT07153471
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Not yet reported Eli Lilly and Company 800 participants Est. completion 2028-05 88 sites Stand-aloneOsteoarthritisView official trial listing → -
Recruiting NCT NCT07202884
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Not yet reported Eli Lilly and Company 1000 participants Est. completion 2028-03 136 sites Stand-aloneOther conditions: Urinary Incontinence,StressView official trial listing → -
Recruiting NCT NCT07223593
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Not yet reported Eli Lilly and Company 1205 participants Est. completion 2028-06 161 sites Stand-aloneOther conditions: Peripheral Arterial DiseaseView official trial listing → -
Recruiting NCT NCT07241390
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Not yet reported Eli Lilly and Company 7140 participants Est. completion 2031-08 566 sites Stand-aloneCardiovascular diseaseChronic kidney diseaseView official trial listing → -
Recruiting NCT NCT07613307
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Not yet reported Eli Lilly and Company 130 participants Est. completion 2027-05 40 sites Stand-aloneType 2 diabetes Other conditions: Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders, Nutritional and Metabolic Diseases, Endocrine System Diseases, Feeding Behavior, Behavior, Fasting, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide Receptors, Receptors, G-Protein-Coupled, Receptors, Cell Surface, Membrane Proteins, Proteins, Receptors, PeptideView official trial listing → -
Completed NCT NCT03929744
A Study of LY3502970 in Healthy Participants
Not yet reported Eli Lilly and Company 133 participants Est. completion 2020-11-02 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT04426474
A Study of LY3502970 in Participants With Type 2 Diabetes
Not yet reported Eli Lilly and Company 68 participants Est. completion 2021-07-12 6 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04680767
A Study of LY3502970 in Healthy Male Participants
Not yet reported Eli Lilly and Company 6 participants Est. completion 2021-07-03 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT05048719
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Not yet reported Eli Lilly and Company 383 participants Est. completion 2022-09-30 44 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT05051566
A Multiple Dose Study of LY3502970 in Healthy Participants
Not yet reported Eli Lilly and Company 26 participants Est. completion 2022-04-04 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT05051579
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Not yet reported Eli Lilly and Company 272 participants Est. completion 2022-11-22 35 sites Stand-aloneOther conditions: Obesity, Overweight and ObesityView official trial listing → -
Completed NCT NCT05086445
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
Not yet reported Eli Lilly and Company 62 participants Est. completion 2022-09-05 5 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT05110794
A Multiple-Dose Study of LY3502970 in Healthy Participants
Not yet reported Eli Lilly and Company 34 participants Est. completion 2022-02-10 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT05313802
A Study of LY3502970 in Healthy Overweight and Obese Participants
Not yet reported Eli Lilly and Company 72 participants Est. completion 2022-09-09 3 sites Stand-aloneOther conditions: Healthy, ObeseView official trial listing → -
Completed NCT NCT05341089
A Study of Two Different Formulations of LY3502970 in Healthy Participants
Not yet reported Eli Lilly and Company 39 participants Est. completion 2022-09-01 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT05469126
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
Not yet reported Eli Lilly and Company 26 participants Est. completion 2022-11-03 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT05573230
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
Not yet reported Eli Lilly and Company 32 participants Est. completion 2023-01-17 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT05803421
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Not yet reported Eli Lilly and Company 2749 participants Est. completion 2026-03-16 358 sites Stand-aloneType 2 diabetesCardiovascular diseaseChronic kidney disease Other conditions: Obesity, Overweight or Obesity, OverweightView official trial listing → -
Completed NCT NCT05841238
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
Not yet reported Eli Lilly and Company 52 participants Est. completion 2023-11-13 3 sites Stand-aloneOther conditions: Healthy, ObeseView official trial listing → -
Active, not recruiting NCT NCT05869903
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Not yet reported Eli Lilly and Company 3127 participants Est. completion 2027-10 138 sites Stand-aloneOther conditions: Obesity, Overweight, Overweight or ObesityView official trial listing → -
Completed NCT NCT05872620
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Not yet reported Eli Lilly and Company 1613 participants Est. completion 2025-08-08 136 sites Stand-aloneType 2 diabetes Other conditions: Obesity, OverweightView official trial listing → -
Completed NCT NCT05882032
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
Not yet reported Eli Lilly and Company 29 participants Est. completion 2024-11-18 4 sites Stand-aloneOther conditions: Healthy, Hepatic InsufficiencyView official trial listing → -
Completed NCT NCT05931380
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Not yet reported Eli Lilly and Company 238 participants Est. completion 2025-06-19 16 sites Stand-aloneOther conditions: ObesityView official trial listing → -
Completed NCT NCT05936138
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.
Not yet reported Eli Lilly and Company 24 participants Est. completion 2024-04-11 4 sites Stand-aloneOther conditions: Renal Insufficiency, HealthyView official trial listing → -
Completed NCT NCT05971940
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Not yet reported Eli Lilly and Company 559 participants Est. completion 2025-04-03 89 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT06010004
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Not yet reported Eli Lilly and Company 401 participants Est. completion 2025-06-05 40 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT06023095
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
Not yet reported Eli Lilly and Company 24 participants Est. completion 2024-07-29 3 sites Stand-aloneOther conditions: Overweight, ObesityView official trial listing → -
Completed NCT NCT06045221
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Not yet reported Eli Lilly and Company 1698 participants Est. completion 2025-08-22 131 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT06085482
A Phase I Study of LY3502970 in Healthy Participants
Not yet reported Eli Lilly and Company 10 participants Est. completion 2024-01-05 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT06109311
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Not yet reported Eli Lilly and Company 546 participants Est. completion 2025-09-15 70 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT06186622
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
Not yet reported Eli Lilly and Company 50 participants Est. completion 2024-07-10 2 sites Stand-aloneOther conditions: Healthy, Obese, OverweightView official trial listing → -
Completed NCT NCT06192108
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Not yet reported Eli Lilly and Company 962 participants Est. completion 2025-09-26 74 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT06370728
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
Not yet reported Eli Lilly and Company 30 participants Est. completion 2024-07-23 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT06440980
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Not yet reported Eli Lilly and Company 533 participants Est. completion 2025-06-02 7 sites Stand-aloneOther conditions: Healthy, Obese, Overweight, ObesityView official trial listing → -
Completed NCT NCT06584916
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Not yet reported Eli Lilly and Company 376 participants Est. completion 2025-11-21 29 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Active, not recruiting NCT NCT06649045
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Not yet reported Eli Lilly and Company 600 participants Est. completion 2027-01 66 sites Stand-aloneObstructive sleep apnea Other conditions: Overweight or ObesityView official trial listing → -
Completed NCT NCT06692348
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
Not yet reported Eli Lilly and Company 86 participants Est. completion 2025-06-09 3 sites Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT06704763
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
Not yet reported Eli Lilly and Company 27 participants Est. completion 2025-02-05 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT06824051
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
Not yet reported Eli Lilly and Company 120 participants Est. completion 2026-01-26 4 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Active, not recruiting NCT NCT06948422
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Not yet reported Eli Lilly and Company 974 participants Est. completion 2027-09 100 sites Stand-aloneOther conditions: HypertensionView official trial listing → -
Active, not recruiting NCT NCT06948435
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Not yet reported Eli Lilly and Company 487 participants Est. completion 2027-09 99 sites Stand-aloneOther conditions: Hypertension, Overweight or ObesityView official trial listing → -
Active, not recruiting NCT NCT06952530
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Not yet reported Eli Lilly and Company 487 participants Est. completion 2027-09 99 sites Stand-aloneOther conditions: HypertensionView official trial listing → -
Active, not recruiting NCT NCT06972459
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Not yet reported Eli Lilly and Company 800 participants Est. completion 2027-08 80 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Active, not recruiting NCT NCT06972472
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Not yet reported Eli Lilly and Company 600 participants Est. completion 2027-08 80 sites Stand-aloneType 2 diabetes Other conditions: Obesity, OverweightView official trial listing → -
Active, not recruiting NCT NCT06993792
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Not yet reported Eli Lilly and Company 1400 participants Est. completion 2027-08 80 sites Stand-aloneType 2 diabetes Other conditions: Obesity, OverweightView official trial listing → -
Not yet recruiting NCT NCT07668336
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Not yet reported Eli Lilly and Company 170 participants Est. completion 2030-03 71 sites Stand-aloneType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07729332
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
Not yet reported Massachusetts General Hospital 60 participants Est. completion 2031-07-31 1 siteOther conditions: ObesityView official trial listing → -
Not yet recruiting NCT NCT07739537
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
Not yet reported Massachusetts General Hospital 100 participants Est. completion 2030-09-30 Stand-aloneOther conditions: Diabete Type 2, Pharmacogenomic Drug InteractionView official trial listing → -
Not yet recruiting NCT NCT07790861
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
Not yet reported Eli Lilly and Company 192 participants Est. completion 2028-03 13 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Not yet recruiting NCT NCT07793019
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 104 participants Est. completion 2028-01-26 1 siteOther conditions: Overweight, Healthy Participants, ObesityView official trial listing → -
Not yet recruiting NCT NCT07794579
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Not yet reported Eli Lilly and Company 2001 participants Est. completion 2030-09 179 sites Stand-aloneOther conditions: Overweight, Prediabetic State, Prehypertension, Obesity, AbdominalView official trial listing →
Efficacy history
Absolute change weight loss · 80 weeks
Adults with obesity or overweight, without type 2 diabetes
Trial: TRIUMPH-1 (Phase 3)
Source →Results from different trials are not directly comparable — populations, timepoints, and measurement methods differ between studies.
Safety
Not yet reported.
Sources
Also known as: Orforglipron, LY3502970
Related On The Pen coverage
No related coverage yet.
Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.